tenosynovial giant cell tumor

At ASCO, Merck KGaA Shows How Its Drug Measures Up as Treatment for Rare Type of Tumor

Merck KGaA’s pimicotinib led to statistically significant improvement on multiple measures of its Phase 3 test in tenosynovial giant cell tumor, positioning the drug to potentially compete with medications from Daiichi Sankyo and Ono Pharma. The Phase 3 results were presented during the annual meeting of the American Society of Clinical Oncology.

By Frank Vinluan

Pharma, BioPharma

Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor

Romvimza, a drug for treating tenosynovial giant cell tumor, was initially developed by Deciphera Pharmaceuticals. Last year, Ono Pharmaceutical acquired Deciphera to build up its oncology portfolio and expand its business prospects in the U.S. and Europe.

By Frank Vinluan